Navigation Links
Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators
Date:7/1/2013

transmit signals to promote cancer and of how these signals become altered in the context of acquired resistance to ALK inhibitors. Her work will identify novel targets that can be blocked in combination with ALK inhibitors, to promote enhanced anti-tumor responses. Since ALK mutations have been described in a growing number of hematologic and solid organ tumors, an improved understanding of ALK signalingas well as mechanisms of resistance to ALK inhibitionmay also have potential implications for other cancers.

Dr. Lovly works under the mentorship of William Pao, MD, PhD, at Vanderbilt University School of Medicine, Nashville, Tennessee.

Ann Mullally, MD

Myeloproliferative neoplasms (MPN) are a type of blood cancer sometimes considered to be "pre-leukemias" which can progress to leukemia and are also lethal cancers in their own right. A population of rare hematopoietic stem cells (HSC), called MPN disease-propagating cells, typically harbor mutations that cause the cells to overproliferate. These mutated HSC produce abnormal cancerous blood cells that over time can eliminate the normal blood cells in the bone marrow. In MPN, the cancerous blood cells secrete an excess of substances called growth factors that allow cancer cells to survive.

Dr. Mullally aims to understand which of the growth factors help the mutated HSC to survive and to then use drugs to block the activity of these growth factors, thus killing the mutated HSC. This approach will lead to more successful treatments for MPN and leukemia, resulting in a higher cure rate for patients.

Dr. Mullally works under the mentorship of Benjamin L. Ebert, MD, and Daniel J. Deangelo, MD, PhD, at Brigham and Women's Hospital, Boston, Massachusetts.

Deepak Nijhawan, MD, PhD

Despite recent advances, lung cancer remains the leading cause of cancer related death in the United States, and there is an urgent need for new therapies. The most successful tr
'/>"/>

Contact: Yung S. Lie
yung.lie@damonrunyon.org
212-455-0521
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology news :

1. Damon Runyon Cancer Research Foundation grants prestigious awards to 17 young scientists
2. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
3. ACRG and BGI report new evidence for the genetic bases of liver cancer
4. Cancer is a result of a default cellular safe mode, physicist proposes
5. Continued research needed on treatment for women with lung cancer who are never smokers
6. TGen and Ventana Medical Systems Inc. join forces to fight cancer
7. National Institutes of Health to fund research probing proteins linked to cancer, diabetes
8. Herding cancer cells to their death
9. No danger of cancer through gene therapy virus
10. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
11. Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... technology and tech stocks, releases video from the CES 2015 ... security consultant Apollo Robbins . Apollo shows ... Wocket™ biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... CLEVELAND University Hospitals (UH) Case Medical Center ... a catheter-based treatment for heart failure, today announced ... Partitioning Device, a Percutaneous Ventricular Restoration Therapy (PVRT) ... The two-year clinical results were presented ...
... to participate in genetic testing that can indicate their ... results does not appreciably drive up or diminish test ... to a study performed by researchers at the National ... The study in the May 17, 2012 early online ...
... Scientists at Queen Mary, University of London have shown ... causes of psychiatric disorders. The study, published online ... zebrafish can modify their behaviour in response to varying ... of Biological and Chemical Sciences who led the study, ...
Cached Biology News:UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure 2UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure 3NIH-led study finds genetic test results do not trigger increased use of health services 2NIH-led study finds genetic test results do not trigger increased use of health services 3NIH-led study finds genetic test results do not trigger increased use of health services 4Zebrafish could hold the key to understanding psychiatric disorders 2
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
(Date:2/26/2015)... February 26, 2015 The Movement for ... to support life extension technologies and awareness. The event ... Coordinated Time, on March 21st 2015, in a live ... , Eric Schulke, Founder of MILE, says, “Our lives ... urgency. The Movement for Indefinite Life Extension is raising ...
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... 2008 - Vol. 299. No. 8: ,Venous Thromboembolism and ... Administration for the Treatment of Cancer-Associated ... believes that,the conclusions of a study published in the ... Medical Association (JAMA) by Bennett, et al, do,not provide ...
... 26 CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported ... 31, 2007., For the quarter ended December 31, 2007, ... per share. This compares to a net loss of,$68.1 million, ... and $34.2,million, or $0.58 per share, for the prior quarter ...
... REINACH, Switzerland, February 26 Arpida Ltd.,(SWX: ARPN) today ... (NDA) for intravenous iclaprim in its first indication,complicated Skin ... next few weeks., Arpida has agreed with the ... in a rolling process. Using a ,rolling NDA, allows ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3
... specifically for high efficiency siRNA ... toxicity reagent proven to work ... of cell types. Results in ... of target gene expression. One ...
... Protein Purification Protocols covers a wide ... for novice and experienced researchers in all ... This excerpt from the books preface illustrates ... to your research library., The chapters introduce ...
... siRNA transfection reagent that has been shown ... variety of cell lines. jetSI-ENDO is serum ... protocol. High levels of gene silencing (up ... 20 to 100 nM of siRNA in ...
... The lower cost and reduced space ... make reference standard DNA analysis technology ... used with any of SEQUENOM's applications ... Genotyping (iPLEXTM Gold) , Gene Expression ...
Biology Products: